Nyrada

NYR.AX

Biotechnology · Healthcare

Price

A$0.74

+0.01 (+0.68%)

Market Cap

A$181.2M

Exchange

Australian Securities Exchange

Winston Score

–

No score yet — Winston is napping.

We couldn’t gather enough financial data to score this stock reliably.

Track this stock — start free trial

Share count rising — dilution

+53.2% over 4y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 156.0M (2022) → 239.0M (2026)

Winston Score History

The full picture

Nyrada Inc. is a small Australian biotech company that discovers and develops new drugs. It focuses on two main areas: treatments for brain injuries caused by strokes or trauma, and drugs that lower cholesterol. The company does not yet sell any approved products — it is still in the early stages of testing its drug candidates in clinical trials.

Nyrada makes no meaningful revenue today. It funds its research by raising money from investors, which is typical for early-stage drug developers. The company is based in Australia but conducts some research activities internationally. Its negative margins reflect heavy spending on research with no product sales to offset costs. The biggest risk Nyrada faces is that its drug candidates may fail in clinical trials, which would make it very difficult to survive without raising additional capital from shareholders.

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

-100.0% YoY

YoY Growth Rate

Revenue declining

EPS Growth

-21.1% YoY

YoY Growth Rate

Earnings declining

R&D Spend

A$3M/ year

↓ Declining (-27% vs prior year)

R&D spend declining — could signal cost-cutting or efficiency

Insider Activity

51.1%ownership

→ Flat

Insider ownership roughly steady over the past year

Cash Runway

5+ years

Quarterly Free Cash Flow

→ Burn rate stable

A$8M cash & investments at current burn rate

Revenue declining

Nyrada's revenue is actually shrinking. In a growth stock, that removes the core investment thesis. The low Winston Score here may be warranted — unless there's a turnaround story.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale

Gross Margin

N/A

Data not available

Profit after running costs

Operating Margin

N/A

Data not available

Return on the money invested

ROCE

-90.0%

Weak — -90.0% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth

Sales YoY

-100.0%

Shrinking sales (-100.0% YoY)

Profit growth

EPS YoY

N/A

Data not available

How steady the profit is

EPS Consistency

3/8 quarters

Earnings rarely grow — volatile business

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash

Cash Conversion

N/A

Data not available

Spare cash per sale

FCF Margin

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns

Debt / Equity

N/A

Data not available

Covers its interest

Interest Cover

N/A

—

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit

P/E Ratio (TTM)

N/M

Negative earnings — P/E not meaningful

Cheaper or dearer next year

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial